These data suggest that in tumours characterised by high BCL-2 levels, and predicted by DR_MOMP to respond favourably to the addition of ABT-199 to FOLFOX, 18F-FDG-PET may be an early response biomarker. The gene discussed is BCL2; the disease is neoplasm.